CADE proposes remedy for GSK/Pfizer

The investigative arm of Brazil’s competition authority has raised concerns that GlaxoSmithKline’s pending acquisition of Pfizer’s consumer healthcare division could lead to higher prices for simple antacids.


Get unlimited access to all Global Competition Review content